<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741010</url>
  </required_header>
  <id_info>
    <org_study_id>ID-BVQ-401</org_study_id>
    <nct_id>NCT03741010</nct_id>
  </id_info>
  <brief_title>Belviq Tablet® Post Marketing Surveillance Protocol</brief_title>
  <official_title>Belviq Tablet® Post Marketing Surveillance Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-marketing surveillance of Lorcaserin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lorcaserin(Belviq) is a selective 5-hydroxytryptamine receptor agonist, witch is used long
      term for weight loss in those who are obese. Lorcaserin was approved in 2015 the Republic of
      Korea for weigh loss in those who are obese. A post-marketing surveillance was conducted
      following the approval to obtain data on the safety and efficacy of lorcaserin for weigh loss
      in real-world practice.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 2, 2015</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse event after this drug administration in general medical</measure>
    <time_frame>12 weeks</time_frame>
    <description>Any adverse events occurred after this drug dosing will be recorded. Description of adverse event(s) including type of adverse event(s), onset/end date, severity, action taken, causal relationship to the drug and investigator's view on the adverse event(s) will be captured, whether it is related to the drug or not and until follow up visit more than 1 time during the surveillance period.
Lab abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to week 12 in the Body Mass Index(BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>BMI is measured before administration of the drug and within 12 weeks after administration.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Weight Loss</condition>
  <eligibility>
    <study_pop>
      <textblock>
        residents of Korea, in real-world practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who use the drug as an adjuvant therapy of diet therapy and kinesitherapy for
        weight control are selected.

          1. Obese patients whose body mass index (BMI) is ≧30 kg/m2.

          2. Overweight patients whose body mass index(BMI) is ≧27 kg/m2 and who have other risk
             factors(e.g. hypertension, dyslipidemia, type II diabetes mellitus)

        Exclusion Criteria:

          1. Patients with a hypersensitivity reaction to the drug or the ingredient of the drug

          2. Female patients of childbearing potential and pregnant or lactating women

          3. Patients taking another weight control drug

          4. Patients with the medical history of drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>November 22, 2018</last_update_submitted>
  <last_update_submitted_qc>November 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

